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Vertebrates harbor a densely populated resident microbial community, which consists of bacteria, viruses and fungi, particularly in mucosal organs, such as the oral cavity and the intestine. This internal microbial community residing in the host is referred as the microbiota 1 . In healthy individuals, Gram-negative Proteobacteria and Bacteroidetes, and Gram-positive Firmicutes, such as Clostridiales and Lactobacillales, are the major phyla among intestinal eubacteria, whereas methanogens are the predominant intestinal archaea 2 . Many of these resident commensals are adapted to the intestinal environment and develop complex ecological networks with other bacteria to acquire nutrients. For example, Lactobacillus spp. and Eubacterium dolichum cannot synthesize certain amino acids and therefore acquire these critical molecules from their intestinal habitats 3, 4 . Methanogens obtain energy from hydrogen molecules, a waste product of other obligate anaerobes 2 . Consequently, host-microbial, microbial-microbial as well as microbial-environmental interactions dictate the distribution of individual commensals throughout the gastrointestinal tract.
A critical factor that defines the composition and distribution of the microbiota is the nutrient requirement of individual commensals ( Fig. 1) . Microbes colonize mammalian hosts immediately after birth 5, 6 . In neonatal mice, the bacterial composition in the oral cavity and intestinal tract is homogenous and simply structured; after weaning, however, as the diet changes from maternal milk to fiber-rich foods, the bacterial composition dramatically changes 5, 6 . The small intestine is rich in monosaccharides and disaccharides as well as amino acids, which support the growth of certain bacteria, particularly Proteobacteria and Lactobacillales (Fig. 1) . In the distal small intestine including the terminal ileum, simple sugars are absorbed by host cells, so energy sources available for bacterial growth are substantially altered, resulting in changes in bacterial composition. Beyond the ileocecal valve, the vast majority of available carbohydrates are diet-derived (from plant foods) or host-derived (for example, mucin, cellular debris and others) complex carbohydrates (polysaccharides), which are indigestible by the host. Proteobacteria, such as Escherichia coli, cannot digest polysaccharides, and therefore cannot use complex carbohydrates as an energy source. In contrast, Bacteroides and Clostridiales have enzymes that can break down host-indigestible polysaccharides, including fibers and mucin, and use them as an energy source. Consequently, the abundance of Proteobacteria and Lactobacillales is much lower in the colon, whereas Bacteroides and Clostridiales are dominant populations in the large intestine 7 . Even among bacteria in the same phylum, the ability to scavenge polysaccharides is highly diverse 7 , suggesting that the polysaccharide content of any diet can greatly affect the relative abundance of bacterial species within Bacteroidetes or Clostridiales. Thus, the distribution of nutrients in the intestine is a major driver of the microbial community structure in the gut. Many studies have shown differences in the composition of microbiota between healthy individuals and patients with intestinal diseases [8] [9] [10] , which may reflect changes in the availability of host factors and nutrients in the disease state and/or be secondary to the inflammatory response. However, the diversity of microbiota among individuals cannot be explained by diet alone. For example, Bifidobacteria, which affect host responses to pathogens, colonize the gut of humans, but not specific pathogen-free mice. Additional ecological analyses of intracommensal interactions and better characterization of the metabolic activities of individual bacteria are required to understand the diversity of bacteria in the intestine. Commensals control pathogens via direct interactions Both pathogens and commensal bacteria require similar ecological niches to colonize and proliferate in the intestine, and mechanisms to outcompete each other have evolved in these bacteria. Commensal bacteria produce bacteriocins, proteinaceous toxins that specifically inhibit members of the same or similar bacterial species 11 . For example, E. coli produces bacteriocin that directly inhibits the growth of the related pathogen, enterohaemorrhagic E. coli (EHEC) 12 (Fig. 2) . Commensals also prevent infection by pathogens by altering host environmental conditions (for example, pH), making them prohibitive for colonization by pathogens 11 . Healthy vaginal flora reduces the pH in the vagina, thereby preventing the colonization by urinary tract pathogens for which the optimal pH for growth is neutral 13 . Likewise, in the intestine, certain commensal bacteria generate shortchain fatty acids, which can alter local pH to inhibit the growth of certain intestinal pathogens 14, 15 (Fig. 2) . Bifidobacterium spp. block colonization by pathogenic E. coli through acidification of its environment 16 . Similarly, optimal pH is critical for the growth of Bacillus cereus and for enterotoxin secretion 17 .
An alternate strategy used by the indigenous microbial community is the preferential consumption of nutrients required for the growth of competing pathogenic bacteria. For example, commensal E. coli competes with EHEC for organic acids, amino acids and other nutrients [18] [19] [20] [21] (Fig. 2) . By consuming common limited resources, the gut microbiota essentially causes the starvation of competing pathogens. Commensal bacteria, through production of specific metabolites, can also affect pathogen virulence to compromise their growth. The short-chain fatty acid butyrate downregulates the expression of several virulence genes including those encoding the type 3 secretion system proteins in Salmonella enterica serovars Enteritidis and Typhimurium 22 (Fig. 2) . Moreover, host mucin-derived fucose, which is generated by fucosidase-bearing commensal bacteria such as Bacteroides thetaiotaomicron, modulates the expression of the virulence factor Ler, a master regulator of the locus of enterocyte effacement ('LEE') genes in EHEC 23 (Fig. 2) . Commensals not only directly, via their metabolites, suppress virulence genes of pathogens, they also inhibit pathogen virulence by altering conditions required for virulence activity. For example, ambient oxygen tension is required for competent secretion of virulence factors by Shigella flexneri 24 , and therefore, the consumption of residual oxygen by commensal facultative anaerobes, such as Enterobacteriaceae, may lead to incomplete expression of virulence factors in the intestinal lumen (Fig. 2) .
Commensals control pathogens by stimulating host immunity Commensal bacteria also prevent pathogen colonization and infection indirectly by enhancing host defense mechanisms, including functionally promoting function of the mucosal barrier and enhancing innate immune responses. The first line of defense against invasion by any pathogen is the epithelial barrier. The idea that commensal bacteria promote function of the epithelial barrier is supported primarily by indirect evidence. Germ-free mice and mice deficient in proteins involved in microbial recognition, such as Nod2 and the TLR signaling adaptor MyD88, have impaired production of antimicrobial peptides, particularly by Paneth cells of the small intestine 25, 26 . Consequently, MyD88-deficient or Paneth cell-deficient mice have impaired epithelial barrier function and increased bacterial translocation of pathogenic bacteria 26 , resulting from their inability to produce specific antimicrobial peptides (Fig. 2) . Additionally, antimicrobial peptides not only limit enteric infection by their inherent bactericidal activity but also restrict bacterial colonization. Specifically, mice deficient in MyD88 or RegIIIγ have higher mucosal bacterial loads compared to their wild-type littermates, with more bacteria in direct contact with the surface epithelium in the small intestine 27 . Production of RegIIIγ is also upregulated by interleukin 22 (IL-22), which is induced in group 3 innate lymphoid cells, interleukin 17-producing T helper (T H 17) cells as well as a certain subset of dendritic cells [28] [29] [30] by the gut microbiota. IL-22-mediated production of RegIIIγ by intestinal epithelium is protective against enteric infection by Citrobacter rodentium, a mouse bacterium that models infection by enteropathogenic E. coli (EPEC) and EHEC 28, 31, 32 (Fig. 2) . In addition to resulting in the production of antimicrobial peptides, bacterial signaling, likely through MyD88, also promotes the barrier function through the production of secretory IgA that is released by intestinal epithelial cells, binds to microbial antigens, neutralizes pathogen activity and prevents infection [33] [34] [35] [36] . However, because both antimicrobial peptides and IgA also can shape gut microbiota 27, [37] [38] [39] , it remains unclear whether the actual composition of the gut microbiota regulated by these molecules is the main determinant for pathogen resistance. The gut microbiota not only promotes mucosal barrier function but also enhances host immunity to defend against enteric infection. IL-1β is a cytokine typically produced during active infection that is critical (mainly Enterobacteria), Lactobacillales and Erysipelotrichales (especially Turicibacter spp.) are dominant in the small intestine. In contrast, the large intestine is poor in such nutrients and therefore has fewer of these bacteria, whereas Bacteroidetes and Clostridia, which can use host-indigestible fibers as energy sources, are enriched.
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r e v i e w for recruitment of neutrophils and eradication of pathogens. The microbiota have an essential role in the production of homeostatic levels of pro-IL-1β in resident intestinal macrophages that is dependent on MyD88, thereby priming macrophages to respond rapidly to enteric infection by conversion of pro-IL-1β to mature active IL-1β 40 ( Fig. 2) . The gut microbiota can also enhance host immunity through MyD88-independent mechanisms. Notably, colonization of germ-free mice by commensal bacteria induces development of T H 17 cells in the intestine, which is important for protection against C. rodentium infection and is independent of MyD88, TRIF and Rip2 (ref. 41 ).
Disruption of the microbiota leads to pathogen outgrowth A consequence of the disruption of commensal-mediated resistance to colonization is markedly greater susceptibility to enteric infection. S. enterica serovar Typhimurium (here referred to as Salmonella) colonize poorly the mouse intestine in the presence of commensal microbiota 42 . However, it can proliferate and induce inflammation if the resident bacterial community is disrupted by treatment with antibiotics or if recipient mice have low-complexity microbiota 42, 43 . An altered bacterial community structure also may facilitate the overgrowth of potentially harmful subsets of indigenous bacteria in the intestine. In a mouse model, virulent E. coli, whose growth is normally suppressed by commensal bacteria, accumulates after treatment with antibiotics and can disseminate systemically when the intestinal epithelial barrier is breached by dextran sulfate sodium (DSS), thereby inducing activation of the inflammasome, which is lethal to the mouse 44 . Similarly, Clostridium difficile, a leading cause of the healthcare-associated infectious diarrhea and colitis 45 , is typically present at low abundance in the intestine of healthy adult individuals. Disruption of indigenous bacteria after treatment with broad-spectrum antibiotics, as in hospitalized patients, can lead to a substantial increase in the abundance of C. difficile, followed by severe intestinal inflammation 45 . As is the case in humans, in a mouse model of C. difficile infection, C. difficile cannot colonize and induce inflammation in conventional mice, whereas treatment with antibiotic increases the incidence of C. difficile infection. C. difficile does not invade the host systemically but causes marked epithelial damage through the production of the toxins TcdA and TcdB 45, 46 (Fig. 2) . The toxin-mediated epithelial damage can cause systemic dissemination of commensal bacteria, which induce lethal septic shock 47 (Fig. 2) . Vancomycin-resistant Enterococcus (VRE), which can cause sepsis in immunocompromised patients, is also associated with antibiotic treatment 48 . Commensal microbiota-mediated induction of antimicrobial peptide RegIIIγ is particularly important for bacterial killing (Fig. 2) . A role for commensals in the regulation of the production of RegIIIγ is supported by the observation that bacterial signaling through MyD88 and, more specifically, administration of the bacterial products lipopolysaccharide or bacterial flagellin, upregulate RegIIIγ and increase eradication of VRE 49, 50 . However, a recent study suggested that specific bacterial populations in the colon facilitate clearance of VRE that occurred independently of host innate immune pathways including MyD88 (ref. 51) . Although the mechanism is currently unknown, it may be related to a direct mechanism, such as competition for limited nutrients. It is also possible that both commensal-dependent indirect and direct mechanisms are essential for clearance of VRE, with production of antimicrobial peptides being the primary mechanism in the small intestine, where Paneth cells predominate, and direct inhibition by specific bacteria populations being a primary mechanism in the colon.
The gut microbiota as promoters of enteric infection
Although the commensal microbiota has crucial roles in resistance to enteric pathogen infections, certain pathogens can use the microbiota to facilitate their infection. For example, by-products derived Figure 2 Commensal microbiota prevents colonization by exogenous pathogens and pathobionts. In the healthy gut, the resident bacteria occupy intestinal colonization niches. Commensal microbiota suppresses the proliferation and colonization of incoming enteric pathogens, as well as of opportunistic pathobionts, through multiple mechanisms. Microbiota produces bacteriocins and short-chain fatty acids, which directly inhibit the growth of pathogens and pathobionts. Commensals can also modify virulencefactor expression in pathogens by consuming residual oxygen or suppressing growth by their metabolites. Commensal microbiota facilitates host barrier function through upregulation of the mucus layer, induction of antimicrobial molecules, such as RegIIIβ and γ (RegIII), and regulating secretion of IgA. Commensal bacteria also prime intestinal macrophages by upregulating pro-IL-1β. Pathogen infection results in the conversion of pro-IL-1β into the enzymatically active mature form of IL-1β, which promotes neutrophil recruitment and pathogen eradication. Commensal microbiota promotes differentiation and/or activation of T H 17 cells and innate lymphoid cells (ILCs), which control both commensals and pathogens through secreted cytokines, such as IL-22. Antibiotic treatment or other environmental factors that disrupt the commensal microbial community result in diminished resistance to colonization by pathogens (for example, Salmonella and S. flexneri) and allow the outgrowth of indigenous pathobionts (for example, C. difficile and VRE) that have the potential to disseminate systemically and induce septic shock and/or systemic organ infection. 
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r e v i e w from commensal bacteria such as bile salts promote the germination of C. difficile spores 52 . In addition to bacterial pathogens, certain enteric viruses can also take advantage of the gut microbiota to promote their replication and transmission. Transmission of mouse mammary tumor virus (MMTV) to offspring and replication of poliovirus are substantially reduced in antibiotic-treated or germ-free mice 53, 54 . These enteric viruses directly bind and modify the stimulatory activity of lipopolysaccharide that is secreted by commensal bacteria. MMTV-bound lipopolysaccharide induces the production of the anti-inflammatory cytokine IL-10, which leads to depressed antiviral immune response by the host and persistent infection of MMTV 53 . Thus, the microbiota can also potentiate pathogenic infection.
Pathogen strategies to overcome resistance by commensals As described above, microbiota have developed multiple mechanisms to resist colonization by pathogens. However, pathogens have evolved strategies to escape these mechanisms. For example, to counteract nutritional competition by commensals, some pathogens have evolved to use alternative nutrients. The pathogen EHEC can use galactose, hexuronates, mannose and ribose as carbon sources for its growth, whereas commensal E. coli cannot catabolize these sugars 20, 55 (Fig. 3) . In addition to having altered carbohydrate metabolism, EHEC has the eut operon in its genome for metabolism of ethanolamine and can use pathogen-specific nutrients in the intestine, such as ethanolamine, which is released into the intestine during epithelial cell turnover 20, 56, 57 (Fig. 3) . In contrast, the eut operon is absent in the genomes of commensal members of nonpathogenic E. coli, thereby prohibiting them from using ethanolamine as a nutrient 57 . Although C. rodentium exhibits a similar carbohydrate metabolic profile as the commensal E. coli 58 , C. rodentium resides in a distinct niche during replication, allowing it to avoid competing for nutrition with the commensals. Specifically, C. rodentium expresses intimin, a LEE-encoded adhesion molecule, that allows the bacterium to localize to the intestinal epithelial surface, where commensal microbiota do not normally reside 58 (Fig. 3) .
In addition, some pathogens use common resources more efficiently. Iron is an essential resource for the growth of bacteria, and many bacteria produce iron-chelating small molecules, known as siderophores, to acquire ferric iron 59 . Host cells secrete lipocalin 2 (Lcn2), which blocks the 2,3 dihydroxy benzoate-based siderophore enterobactin (Ent) in E. coli, thereby preventing iron acquisition and proliferation of commensal E. coli. However, some enteric pathogens, such as Salmonella, pathogenic E. coli and Klebsiella pneumoniae, display modified forms of Ent, referred to as salmochelins (also, enteric pathogens vary the positioning of hydroxyl groups to the 3,4 positions or use noncatecholate siderophores) 60 . Lcn2 does not inhibit salmochelin-mediated iron uptake, leading to a growth advantage of the pathogens over the commensals (Fig. 3) . Thus, enteric pathogens use different strategies to overcome colonization resistance by using pathogen-specific nutritional resources and/or localizing to distinct niches separate from competing commensals.
Another important strategy pathogens use to acquire a growth advantage over commensals is to promote host inflammation that impedes survival of commensal bacteria. Most virulent microorganisms express virulence factors that cause intestinal inflammation. Inflammation caused by toxin-or pathogen-mediated diarrhea substantially decreases the number of commensal microbiota in the intestine and, in turn, increases the chance of colonization and/or proliferation of incoming pathogens because of less competition 61 . DSS-induced intestinal inflammation markedly increases the proliferation of C. rodentium in the intestine; however, specific virulence factors are required for optimal colonization and proliferation as the 
npg t h e m i c r o b i o ta
r e v i e w ler mutant C. rodentium, which does not express LEE-encoded virulence genes is avirulent and does not acquire a survival advantage from DSS-induced inflammation 58 (Fig. 3) . Recent evidence also demonstrates that Salmonella benefits from intestinal inflammation triggered by the pathogen itself. In the intestine, commensals produce abundant hydrogen sulfide (H 2 S), and the epithelium converts H 2 S to thiosulphate (S 2 O 3 2− ) to avoid the H 2 S-mediated toxic effects on host cells. Infection by Salmonella results in the recruitment of neutrophils that produce reactive oxygen species, resulting in the conversion of S 2 O 3 2− into tetrathionate (S 4 O 6 2− ) 62, 63 . Unlike commensals, Salmonella contains the operon ttrSR ttrBCA that allows the use of S 4 O 6 2− , which provides a growth advantage to Salmonella over commensal microbes in an inflamed environment 64 (Fig. 3) . Moreover, S 4 O 6 2− supports anaerobic growth of Salmonella on ethanolamine 65 (Fig. 3) .
Like Salmonella, pathogenic E. coli including EPEC and EHEC, and C. rodentium, also may benefit from intestinal inflammation. In the inflamed intestine, intestinal epithelium and recruited neutrophils and macrophages that express inducible nitric oxide synthetase, upregulate the production of nitrate (NO 3 − ) 66, 67 . Obligate anaerobes, such as Bacteroidetes or Firmicutes, which comprise the vast majority of healthy microbial community in the gut, cannot use nitrate as an electron acceptor 68 . Rather, nitrate reductase-harboring facultative anaerobes, such as E. coli, can use NO 3 − to generate energy for growth, leading to a growth advantage over obligate anaerobes in the inflamed intestine 68 . Although this mechanism of E. coli overgrowth in the inflamed gut involves commensal-commensal competition, pathogenic E. coli strains, which have nitrate-reductase genes such as narZ in their genome, may use a similar mechanism to acquire a growth advantage over the competitive commensal community (Fig. 3) . Furthermore, the host inflammatory environment can act as a signal to trigger and enhance expression of virulence factors. The human opportunistic pathogen Pseudomonous aeruginosa can bind to interferon-γ through its outer membrane protein OprF, thereby expressing quorum sensing-dependent virulence determinant type I P. aeruginosa (PA-I) lectin 69 . Thus, pathogens can take advantage of the inflammatory response to promote their growth in host tissues.
Microbiota-targeted therapies for disease treatment
The notion of harnessing the gut microbiota to prevent or fight microbial infection is not new. However, the lack of knowledge about the mechanisms by which commensals regulate colonization resistance against pathogens has hampered progress in the area. Recent mechanistic insight into pathogen-commensal interactions suggests ways to promote the eradication of pathogens. Diarrheagenic E. coli strains, including EPEC and EHEC, cause substantial morbidity and mortality worldwide each year 70 . In the C. rodentium model, the capacity to metabolize simple sugars regulates the ability of commensals such as E. coli to outcompete the pathogen for energy resources. Thus, administration of commensals metabolically related to EPEC or EHEC or treatment with prebiotics to boost the growth of natural 'competitors' may prove effective in the treatment of these enteric diseases. Eradication of EPEC and EHEC by commensals could be boosted by targeting pathogen LEE-encoded virulence factors during the early phase of infection 58 . This approach may be effective in eradicating not only enterovirulent E. coli infection but also other intestinal infections by pathobionts such as C. difficile and VRE. Overgrowth of C. difficile and VRE are leading causes of healthcare-associated infectious diarrhea and colitis 45, 48 . There is also evidence that specific bacterial populations in the gut promote clearance of C. difficile and VRE 51, 71 . Although the mechanism is currently unknown, it may be also mediated via a direct mechanism such as through competition between VRE and certain commensals for limited nutrients. Notably, transplantation of intestinal microbiota, which is the infusion of stool microorganisms from a healthy donor, has proved effective in treating recurrent C. difficile infection that is refractory to antibiotic therapy [71] [72] [73] . However, the variability of donor commensal populations and the potential presence of hazardous microbes may hamper the use of microbiota transplantation in the clinic. Thus, identification and characterization of the gut commensals that restrain the growth of C. difficile and VRE may lead to the use of single species or defined combinations of protective commensals to treat infections. In addition, understanding the metabolic pathways that are used by gut commensals to prevent the growth of C. difficile and VRE may lead to the development of genetically engineered commensal species with enhanced capacity to limit pathogen colonization.
Conclusions
Recent studies have provided insight into the mechanisms by which the microbiota regulates colonization and eradication of pathogens. Particularly revealing have been studies that indicate that the ability of commensals to restrain pathogen growth is dictated by metabolic pathways that control competition for limited nutrients in the intestine. Furthermore, inflammatory responses have profound effects on the growth of pathogens and certain commensal species. However, the relative contributions of each metabolic pathway and the commensal species involved remain poorly understood, and little is known about how the inflammatory responses affect interactions between pathogens and commensals. There is a delicate balance in microbiota populations in the gut, and disruption in this balance leads to dysbiosis and overgrowth of pathobionts, leading to pathologic immune responses and disease. The identification and characterization of natural 'competitors' that suppress the growth of pathogens and pathobionts may lead to the development of rational approaches to manage intestinal disease. There is also a clear role for host immunity in controlling populations of microbiota. Recent studies, however, have challenged a critical role of innate recognition receptors in determining the composition of the gut microbiota 74 . Additional studies are needed to clarify the mechanism by which the host regulates the microbiota.
